Zaltrap Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing colorectal cancer incidence rates, advancement of monoclonal antibody therapies, expansion of hospital oncology departments, early clinical adoption of vegf inhibitors, improved diagnostic capabilities.

The growth in the forecast period can be attributed to increasing demand for personalized oncology treatments, rising investment in cancer biologics, expansion of oncology care access in emerging markets, growing focus on combination targeted therapies, continued innovation in angiogenesis inhibition. Major trends in the forecast period include increasing use of targeted anti-angiogenic therapies, growing adoption of combination chemotherapy regimens, rising focus on biomarker-driven treatment selection, expansion of oncology infusion infrastructure, enhanced monitoring of treatment outcomes.

The rising prevalence of colorectal cancer is expected to drive the growth of the Zaltrap market. Colorectal cancer originates in the colon or rectum, often beginning as benign polyps that can progress if untreated. Its prevalence is increasing due to factors such as an aging population, unhealthy diets, obesity, and genetic predisposition. Zaltrap, a vascular endothelial growth factor (VEGF) inhibitor, prevents the formation of new blood vessels (angiogenesis), cutting off the tumor’s blood supply. This action slows disease progression and improves survival outcomes for colorectal cancer patients. For instance, in July 2024, Bowel Cancer UK reported that around 44,000 people are diagnosed with bowel cancer annually in the UK, with over 90% of cases occurring in individuals aged 50 and older, though more than 2,600 cases affect those under 50. Therefore, the rising prevalence of colorectal cancer is driving the growth of the Zaltrap market.

The growing aging population is further propelling the Zaltrap market. An aging population refers to a demographic shift where the proportion of individuals aged 60 or 65 and above increases. This trend is driven by declining fertility rates, increased life expectancy, and social and economic structures supporting older adults. Zaltrap offers an effective treatment for metastatic colorectal cancer, which is more common in the elderly. By blocking VEGF and inhibiting tumor growth, it improves outcomes, slows disease progression, and enhances quality of life for older patients. For example, in January 2024, the Population Reference Bureau reported that the population of Americans aged 65 and older is projected to grow from 58 million in 2022 to 82 million by 2050, representing a 47% increase, with their share of the total population rising from 17% to 23%. Therefore, the growing aging population is driving the growth of the Zaltrap market.

Increasing expenditure on cancer care is also expected to fuel the growth of the Zaltrap market. Cancer care expenditure includes costs related to prevention, diagnosis, treatment, and follow-up care, encompassing both medical and non-medical expenses. Rising spending is driven by the increasing incidence of cancer, advancements in medical technology, and the growing number of cancer survivors requiring long-term management. Higher cancer care investment emphasizes the adoption of targeted and effective treatments like Zaltrap, while supporting research and clinical trials that advance its use. For instance, in September 2024, Cancer Research UK reported that £399 million ($414.65 million) was spent on cancer research in 2023/24, with £93 million ($96.64 million) allocated to research on all types of cancer and £84 million ($87.29 million) directed toward basic cancer biology research. Therefore, increasing expenditure on cancer care is driving the growth of the Zaltrap market.

Major companies operating in the zaltrap market are Sanofi S.A.

North America was the largest region in the zaltrap market in 2025. The regions covered in the zaltrap market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the zaltrap market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the zaltrap market by increasing costs of imported biologic drug substances, sterile manufacturing equipment, infusion packaging, and cold-chain transportation services. Oncology centers in North America and Europe are most affected due to dependence on cross-border biologics manufacturing and distribution networks, while emerging markets face higher import costs. These tariffs contribute to elevated treatment expenses and reimbursement pressures. However, they also encourage localized biologics production, regional fill-finish expansion, and long-term investments in domestic oncology manufacturing capabilities.

The zaltrap market research report is one of a series of new reports that provides zaltrap market statistics, including zaltrap industry global market size, regional shares, competitors with a zaltrap market share, detailed zaltrap market segments, market trends and opportunities, and any further data you may need to thrive in the zaltrap industry. This zaltrap market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Zaltrap is a prescription medication used in combination with chemotherapy to treat metastatic colorectal cancer (mCRC). It functions as a VEGF inhibitor, blocking VEGF-A, VEGF-B, and placental growth factor (PlGF) to prevent angiogenesis, thereby limiting the formation of new blood vessels that tumors need to grow and spread. This helps slow disease progression.

The main indications for Zaltrap are metastatic colorectal cancer (mCRC) and metastatic breast cancer. Metastatic colorectal cancer refers to advanced colorectal cancer that has spread to distant organs such as the liver or lungs. Zaltrap is available in injectable formulations (100 mg/4 ml, 200 mg/8 ml) and is distributed through hospitals, oncology clinics, and pharmacies. It is used by adult and geriatric patients.

The zaltrap market consists of sales of single-dose vials, prefilled syringes, and lyophilized powder for reconstitution. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.